The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst
: Congratulations on another good quarter. Mitch, maybe just firstly, coming back to COVID-19 a little bit. Can you help us think how you're thinking
about VERU-111's position in the market and maybe, obviously, you just try frame -- obviously, it's early before we get through the Phase II trial,
but the market opportunity for VERU-111 there, obviously -- well, I think, earlier line treatments, vaccines. So how do we -- how should we think
about that market opportunity for 111 in COVID if we're successful there?
And then secondly, we talked about potential for VERU-111 to be effective against mutant strains. Do you think the FDA will ask you for an inclusion
criteria to include some of these mutant strains in the Phase III trial?
And then lastly, maybe I'll just ask this one of [TADFIN]. Can you talk about having the financial flexibility to fund all your programs? Obviously,
you've got -- going to have -- you've got a lot going on, sort of probably trials of about 600 patients, if I heard correct, this year. You've got the
manufacturing scale-up for TADFIN. So can you just give us some color in terms of how much wiggle room do you have in that statement?
Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst
: Sorry, just one thing I wanted to follow up, and it's a little bit kind of segue from the last question. Can you just talk about the barriers to entry on
the FC2 business?
|
